Truist sets Medincell stock Buy rating, EUR22 price target

Published 28/05/2025, 05:18
Truist sets Medincell stock Buy rating, EUR22 price target

On Wednesday, Truist Securities initiated coverage on Medincell SA (EPA:MEDCL:FP), assigning a Buy rating and setting a price target of EUR22.00. The new rating underscores the firm’s positive outlook on the company’s prospects within the long-acting injectable (LAI) market, which is anticipated to exceed $20 billion.

Medincell’s BEPO technology, a cornerstone of its operations, has garnered significant industry attention, securing the company upwards of $2.2 billion in potential milestones through strategic partnerships with pharmaceutical giants such as Teva and AbbVie (NYSE:ABBV). These collaborations serve to reinforce Medincell’s stature within the biotech sector as a significant contributor to the advancement of next-generation drug delivery systems.

The company’s internal pipeline also offers a range of potential developments, which Truist Securities refers to as a "call option." This suggests additional upside from Medincell’s ongoing research and development activities.

Looking ahead, the demand for Medincell’s proprietary platform is expected to remain robust. The firm plans to enhance its offerings with the introduction of BEPO STAR, which aims to accommodate a wider variety of molecules and, consequently, a broader spectrum of medical indications.

Truist Securities’ coverage initiation and optimistic price target reflect confidence in Medincell’s technology and market position, as well as the company’s ability to capitalize on the expanding LAI market through both its partnerships and internal pipeline advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.